戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  was sporadically positive in a patient with Stevens-Johnson syndrome.
2 ocular cicatricial pemphigoid>chemical burns>Stevens-Johnson syndrome.
3 dication, should be screened for symptoms of Stevens-Johnson syndrome.
4 rane grafting due to intense inflammation in Stevens-Johnson syndrome.
5 aplasia on amniotic membrane associated with Stevens-Johnson syndrome.
6 ctival squamous metaplasia in a patient with Stevens-Johnson syndrome.
7                 The underlying diseases were Stevens-Johnson syndrome (22 eyes), Sjogren syndrome (11
8                       She was diagnosed with Stevens-Johnson syndrome 5 weeks before.
9                             One patient with Stevens-Johnson syndrome and 2 patients with floppy eyel
10                          Scoring systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) o
11 ty and HLA-B*57:01 and carbamazepine-induced Stevens-Johnson syndrome and HLA-B*15:02 have been imple
12 oat (ENT) lesions are frequently involved in Stevens-Johnson syndrome and toxic epidermal necrolysis
13                                              Stevens-Johnson syndrome and toxic epidermal necrolysis
14        Antibiotics are an important risk for Stevens-Johnson syndrome and toxic epidermal necrolysis
15 wn to be associated with allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
16                                              Stevens-Johnson syndrome and toxic epidermal necrolysis
17                                              Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
18                                              Stevens-Johnson syndrome and toxic epidermal necrolysis
19                                              Stevens-Johnson syndrome and toxic epidermal necrolysis
20 h an increased risk of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis
21                               Although rare, Stevens-Johnson syndrome and toxic epidermal necrolysis
22 ous adverse reactions (SCARs), which include Stevens-Johnson syndrome and toxic epidermal necrolysis,
23 erum levels and the outcome of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
24 valuated for the life-threatening dermatoses Stevens-Johnson syndrome and toxic epidermal necrolysis.
25 ion between enfortumab vedotin treatment and Stevens-Johnson Syndrome and toxic epidermal necrolysis.
26 ne triage system for patients with suspected Stevens-Johnson syndrome and toxic epidermal necrolysis.
27 mmune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrom
28 oration, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with
29 keratopathy, lattice and Avellino dystrophy, Stevens-Johnson syndrome, and chemical/thermal injury.
30 nditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome.
31  are bilaterally blind from diseases such as Stevens-Johnson syndrome, and ocular pemphigoid have lit
32 lated syndromes such as erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
33 mediated, or type I, reactions, anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis
34 disorders such as graft-versus-host disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis
35  approximately 1 month (erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
36               Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe cutaneous drug react
37 iform, granulomatous, erythema multiforme or Stevens Johnson Syndrome, drug rash with eosinophilia an
38 iously to corneal diseases, astigmatism, and Stevens-Johnson syndrome fall within corneal epithelial
39 toxic epidermal necrolysis (IC(025) = 0.95), Stevens-Johnson syndrome (IC(025) = 0.41), drug eruption
40 The most common indications for surgery were Stevens-Johnson syndrome in 41.7% (20 of 48 eyes) and mu
41 patients (chemical injury in 9 [10 eyes] and Stevens-Johnson syndrome in 5 patients).
42 though, it is not clear whether the cause of Stevens-Johnson syndrome in COVID-19 patients is the vir
43                                              Stevens-Johnson syndrome is a well-recognized immune com
44 e vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporal
45 tric oxide in toxic epidermal necrolysis and Stevens-Johnson syndrome may cause the epidermal apoptos
46 with other preoperative diagnoses (excluding Stevens-Johnson syndrome, mucous membrane pemphigoid, an
47  cause, neutropenic sepsis, myocarditis, and Stevens-Johnson syndrome); myocarditis and Stevens-Johns
48  rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1).
49  patients with bronchiolitis obliterans from Stevens-Johnson syndrome often have progressive disease
50    Better BCVA outcomes were observed in the Stevens-Johnson syndrome or toxic epidermal necrolysis (
51 rom seven patients with actively progressing Stevens-Johnson syndrome or toxic epidermal necrolysis.
52 ing the keywords toxic epidermal necrolysis, Stevens-Johnson syndrome, photo-distributed, photo-induc
53                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
54                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
55                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
56 utaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necro
57 notypes, including the blistering conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necro
58 nce of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necro
59                    Cases of photodistributed Stevens-Johnson syndrome (SJS) and toxic epidermal necro
60 severe to life-threatening reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necro
61                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
62                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
63                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
64                                              Stevens-Johnson syndrome (SJS) and toxic epidermal necro
65 ence of epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS) and toxic epidermal necro
66         Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are rare, acute, life-thr
67 ffective ophthalmologic treatments for acute Stevens-Johnson syndrome (SJS) as well as the emerging t
68 cal injury group, and 10 (12 laminae) to the Stevens-Johnson syndrome (SJS) group.
69                                    To report Stevens-Johnson syndrome (SJS) in a patient with acute p
70                               By comparison, Stevens-Johnson syndrome (SJS) is a life-threatening sev
71 tion of drug-induced liver injury (DILI) and Stevens-Johnson syndrome (SJS) or toxic epidermal necros
72                               Three cases of Stevens-Johnson Syndrome (SJS), and 11 cases of Drug Rea
73 vity reactions (DHR) induced by PPI, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolys
74 tively analyzed 74 cases of SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolys
75                                              Stevens-Johnson syndrome (SJS), toxic epidermal necrolys
76 rane transplantation (AMT) for severe ocular Stevens-Johnson Syndrome (SJS), toxic epidermal necrolys
77 e the case of a 7-year-old male patient with Stevens-Johnson syndrome (SJS), which was suspected to b
78 referred to our hospital with a diagnosis of Stevens-Johnson syndrome (SJS).
79 redisposition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysi
80 nced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed to chemothe
81  cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, toxic epidermal necrolysis (SJ
82 a severe complicated adverse event of either Stevens-Johnson syndrome, toxic epidermal necrolysis, or
83 e cutaneous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS
84                                              Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS
85                                              Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS
86 volved in the ocular complications following Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS
87 genesis of severe systemic forms of disease, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS
88                        Patients admitted for Stevens-Johnson syndrome/toxic epidermal necrolysis over
89 nical ventilation is required in one of four Stevens-Johnson syndrome/toxic epidermal necrolysis pati
90                     Prompt identification of Stevens-Johnson syndrome/toxic epidermal necrolysis pati
91                                       In the Stevens-Johnson syndrome/toxic epidermal necrolysis subg
92                                              Stevens-Johnson syndrome/toxic epidermal necrolysis was
93 sinophilia and systemic symptoms, and 7 with Stevens-Johnson syndrome/toxic epidermal necrolysis).
94 R were included, including 236 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, 86
95 nophilia and systemic symptoms syndrome, and Stevens-Johnson syndrome/toxic epidermal necrolysis, can
96 dence of various nail changes as sequalae to Stevens-Johnson syndrome/toxic epidermal necrolysis.
97                According to the examination, Stevens-Johnson syndrome was diagnosed and the patient w
98 d Stevens-Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pemb